{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-048293","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-12-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.074574+00:00","generated_at":"2026-05-29T10:13:07.744591+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Senti Biosciences releases initial Phase 1 clinical data for SENTI-202; no specific results disclosed in filing","bullets":["Initial clinical data from Phase 1 trial of SENTI-202 made available in slide presentation deck.","Data reported under Item 8.01; no specific numeric results or interim analyses provided in the 8-K body.","Company cautions forward-looking statements; risks include clinical trial uncertainties.","Stock ticker SNTI; filing date December 3, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-048293","json":"https://secwatch.observer/filing/0001140361-24-048293.json","markdown":"https://secwatch.observer/filing/0001140361-24-048293.md","text":"https://secwatch.observer/filing/0001140361-24-048293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/0001140361-24-048293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048293/ef20039439_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T10:13:07.744591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}